Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

FOR EVERYONE CYDY is well within the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
Bobbyinvest Member Profile
 
Followed By 10
Posts 1,169
Boards Moderated 0
Alias Born 03/15/17
160x600 placeholder
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/3/2021 5:23:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/2/2021 8:32:38 AM
CytoDyn in discussions with regulators after CD12 data in COVID-19 Seeking Alpha - 2/22/2021 7:08:24 AM
Nextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to $50-60 Million, $8.60 Valuation InvestorsHub NewsWire - 2/22/2021 6:18:20 AM
Nextech AR (OTCQB: NEXCF) 2021 Guidance $50-60 Million Closes 2020 with $20 million. InvestorsHub NewsWire - 2/12/2021 6:26:34 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/5/2021 9:08:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/29/2021 8:32:33 AM
WSGF's, Vaycaychella, Heats Up In $32 Billion Caribbean Vacation Market; Adds Six-Room Hotel To Portfolio Interests InvestorsHub NewsWire - 1/22/2021 9:48:20 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 1/15/2021 4:31:46 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 1/8/2021 8:32:57 AM
The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think InvestorsHub NewsWire - 1/7/2021 8:00:00 AM
PAOG Signals Bullish On CBD Pharmaceutical News With Cannabis Sector Heating Up InvestorsHub NewsWire - 1/6/2021 9:48:29 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 12/30/2020 6:03:52 AM
ALYI ReVolt EV Motorbike Can Capture Huge Share Of African Ride-Share Market; Pre-Orders Reach 2000 Units InvestorsHub NewsWire - 12/29/2020 9:50:07 AM
Biotech Companies; Recent Milestones and Potential Upside InvestorsHub NewsWire - 12/22/2020 8:05:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 12/18/2020 5:41:20 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 12/16/2020 11:00:01 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 12/16/2020 6:04:03 AM
OTC Stocks That Could Skyrocket InvestorsHub NewsWire - 12/10/2020 12:30:12 PM
Companies on the Frontline, Helping Us Through the Pandemic InvestorsHub NewsWire - 11/30/2020 8:35:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/16/2020 4:57:41 PM
Vaycaychella; the Rise of World Series of Golf, Inc. (OTCMKTS: WSGF) InvestorsHub NewsWire - 11/11/2020 9:29:26 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/26/2020 7:55:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/26/2020 7:45:54 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 10/9/2020 8:32:21 AM
Bobbyinvest   Tuesday, 05/12/20 05:07:24 AM
Re: justdafactss post# 77278
Post # of 150206 
FOR EVERYONE CYDY is well within the FDA’s 30-Day Provision

Credit: Another CYDY share holder shared this.

Cytodyn’s Recent Update of BLA Fully Complies With FDA’s 30-Day Provision

For the record, Cytodyn’s original BLA filing on April 27, 2020 and subsequent update by May 11, 2020 is well within the 30-day period expressly provided for by the FDA.
The FDA’s official manual states: “Applications under the PUDUFA Program are allowed to submit stability and clinical safety updates not later than 30 calendar days after receipt of the original application.”
SOPP 8401: Administrative Processing of Original Biologics License Applications (BLA) and New Drug Applications (NDA) Version: 9 Effective Date: February 17, 2020; p.16 D. Filing Decision https://www.fda.gov/media/85659/download
This routine 30-day provision for updates to a BLA after the original application is filed was built into the system by the US Congress to allow for close two-way communication between the PDUFA applicant and the FDA. This provision ensures a more efficient, complete, and effective application process.
The Prescription Drug User Fee Act (PDUFA) applies to applicants submitting BLA’s for biological drugs. Since Leronlimab is a biologic drug, Cytodyn is a PDUFA applicant. This involves payment of a significant fee and fully entitles Cytodyn to all the provisions and exceptions outlined for PUDUFA applicants. This includes the aforementioned provision to update a BLA within 30-days after the original application is filed.
Please refer to the following official FDA guidelines:
https://www.fda.gov/media/85659/download
Center for Biologics Evaluation and Research SOPP 8401
SOPP 8401: Administrative Processing of Original Biologics License Applications (BLA) and New Drug Applications (NDA) Version: 9 Effective Date: February 17, 2020
p. 16 of 35
D. Filing Decision 26. … a. Refer to JA 910.06: Completing a Filing Review for additional information. b. Ensure that the application contains the information and data agreed to during the preBLA/NDA meeting, except for applications under the PDUFA/BsUFA Programs. i. Applications under the PDUFA Program are allowed to submit stability and clinical safety updates not later than 30 calendar days after receipt of the original application.
For further reference:
https://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments
Background and Legislation
The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products. Since the passage of PDUFA, user fees have played an important role in expediting the drug approval process.


https://en.wikipedia.org/wiki/Prescription_Drug_User_Fee_Act#PDUFA_I
The Prescription Drug User Fee Act (PDUFA) was a law passed by the United States Congress in 1992 which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process. The Act provided that the FDA was entitled to collect a substantial application fee from drug manufacturers at the time a New Drug Application (NDA) or Biologics License Application (BLA) was submitted, with those funds designated for use only in Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) drug approval activities. In order to continue collecting such fees, the FDA is required to meet certain performance benchmarks, primarily related to the speed of certain activities within the NDA review process.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences